The genomic and transcriptional landscape of primary central nervous system lymphoma

J Radke, N Ishaque, R Koll, Z Gu, E Schumann… - Nature …, 2022 - nature.com
Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell
lymphomas (DLBCLs) confined to the central nervous system (CNS). Molecular drivers of …

Meta-analysis of MS-based proteomics studies indicates interferon regulatory factor 4 and nucleobindin1 as potential prognostic and drug resistance biomarkers in …

M Ejtehadifar, S Zahedi, P Gameiro, J Cabeçadas… - Cells, 2023 - mdpi.com
Simple Summary Mass spectrometry-based proteomics studies have suggested various
proteins as diagnostic, prognostic, and druggable targets in diffuse large B cell lymphoma …

The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma

X Wang, C Huynh, R Urak, L Weng, M Walter… - Cancer immunology …, 2021 - AACR
Lymphomas with central nervous system (CNS) involvement confer a worse prognosis than
those without CNS involvement, and patients currently have limited treatment options. T cells …

[HTML][HTML] The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an …

TC El-Galaly, D Villa, TY Michaelsen… - European journal of …, 2017 - Elsevier
Purpose Development of secondary central nervous system involvement (SCNS) in patients
with diffuse large B-cell lymphoma is associated with poor outcomes. The CNS International …

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment

L Guo, P Lin, H Xiong, S Tu, G Chen - … et Biophysica Acta (BBA)-Reviews on …, 2018 - Elsevier
Over half of patients with diffuse large B-cell lymphoma (DLBCL) can be cured by standard
R-CHOP treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) …

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high‐dose methotrexate, and R‐DHAP followed by autologous stem cell …

JK Doorduijn, GW van Imhoff… - Hematological …, 2017 - Wiley Online Library
The prognosis of central nervous system (CNS) relapse of systemic non‐Hodgkin lymphoma
is poor with 1‐year survival historically at 0% to 20%. Aiming to improve these results, we …

Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative …

JC Wight, M Yue, C Keane, A Johnston… - British journal of …, 2019 - Wiley Online Library
De novo diffuse large B‐cell lymphoma (DLBCL) presenting with synchronous central
nervous system (CNS) and systemic disease (synDLBCL) is not well described and is …

Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study

C Perry, S Ben Barouch, N Goldschmidt… - American journal of …, 2019 - Wiley Online Library
The incidence of systemic diffuse large B cell lymphoma (DLBCL) concurrently involving the
central nervous system (CNS) at diagnosis, is very low and data regarding the clinical …

Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose …

M Fleming, Y Huang, E Dotson… - Therapeutic …, 2022 - journals.sagepub.com
Background: The optimal treatment of patients with systemic diffuse large B-cell (DLBCL) or
high-grade B-cell (HGBL) lymphomas with synchronous central nervous system (CNS) …

Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma

M Nijland, A Jansen, JK Doorduijn, RH Enting… - Leukemia & …, 2017 - Taylor & Francis
Central nervous system (CNS) involvement in systemic B-cell non-Hodgkin lymphoma (B-
NHL) at diagnosis (sysCNS) is rare. We investigated the outcome of 21 patients with …